Prophylaktische Therapie mit Methylprednisolon und Heparin bei experimentellem Trauma und hämorrhagischem Schock

Klöss, Th.; Bleyl, U.; Brückner, U. B.; Leinberger, H.; Metzker, M.; Saggau, W; Schmier, J

doi:10.1007/978-3-642-67895-0_70

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many demonstrate organ protection and mortality benefit when glucocorticoids are provided at the time of the experimental model of traumatic shock. [15][16][17][18][19][20][21][22][23] Available experimental and observational data suggest a possible cortisol deficiency and potential utility of exogenous steroids in patients suffering traumatic haemorrhagic shock. Owing to the prevalence of traumatic haemorrhagic shock, benefit from a cheap and available drug would have a large impact.…”

Section: Introductionmentioning

confidence: 99%

“…Studies have been performed on a variety of animals utilising a wide range of methods for experimental trauma, with different steroids and doses administered to the subjects. Many demonstrate organ protection and mortality benefit when glucocorticoids are provided at the time of the experimental model of traumatic shock 15–23 …”

Section: Introductionmentioning

confidence: 99%

“…Many demonstrate organ protection and mortality benefit when glucocorticoids are provided at the time of the experimental model of traumatic shock. 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Review article: Early steroid administration for traumatic haemorrhagic shock: A systematic review

Hogarty

Jones

Jassal

et al. 2022

Emerg Medicine Australasia

View full text Add to dashboard Cite

Haemorrhagic shock after trauma is a leading cause of death worldwide, particularly in young individuals. Despite advances in trauma systems and resuscitation strategies, mortality from haemorrhagic shock has not declined over the previous two decades. A proportion of shocked trauma patients may experience a deficiency of cortisol relative to the severity of their injury. The benefit of exogenous steroid administration in patients suffering haemorrhagic shock as a result of injury is unclear. A systematic review of four databases (Ovid Medline, Ovid Embase, Cochrane, Scopus) was undertaken. Inclusion and exclusion criteria were pre‐determined and two reviewers independently screened the articles with disagreements arbitrated by a third reviewer. The primary outcome variable was 28‐day mortality. Quality of studies were assessed using the Cochrane‐risk‐of‐bias (RoB 2) tool. Of the 2919 studies yielded by the search strategy, 1274 duplicates were removed and 1645 screened on title and abstract. After the full text of 33 studies were assessed, two articles were included. Both studies were over 30 years old with small numbers of participants and with primary outcomes not including mortality. Of the data available, no statistically significant difference in mortality was detected. Hospital length of stay, reversal of shock or adverse events were not reported. Both studies were at risk of bias. There are no high quality or recent studies in the English literature investigating the use of steroids for haemorrhagic shocked trauma patients. PROSPERO: CRD42021239656.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review article: Early steroid administration for traumatic haemorrhagic shock: A systematic review

Hogarty

Jones

Jassal

et al. 2022

Emerg Medicine Australasia

View full text Add to dashboard Cite

show abstract

“…2. Andererseits erlaubt sie die Interpretation von am Tiermodell Hund gewonnenen Ergebnissen, beispielweise einer antithrombotisch wirksamen Heparindosierurig, in ihrer vergleichenden Bedeutung fur den Menschen (KLOSS et al, 1982;MISCHKE, 1991).…”

unclassified

Methodische Aspekte für die koagulometrische Aktivitätsbestimmung der Gerinnungsfaktoren II, V, VII und X aus Hundeplasma

Mischke

1994

Journal of Veterinary Medicine Series A

View full text Add to dashboard Cite

Summary Methodological Aspects of the Coagulometric Measurement of Factor II, V, VII and X Activity in Dog Plasma. For optimization of single factor II, V, VII and X activity measurements in dogs, dilution series of dog pool plasma were prepared using different commercially available calcium thrombo plastins and deficient plasmas. Measured by use of a canine reference curve, the single factor activity in humans was 89% (factor II), 13% (factor V), 27% (factor VII) and 84% (factor X). Because the factor V and VII activity in dogs is much higher than in humans, in measurements using human‐deficient plasma, a high sample predilution of at least 1:40 seems to be of advantage. Otherwise extreme variations of the factor V and VII activity may also influence the results of the other single factors. For determination of factor II, V and X activity, therefore, a non‐standardized human placenta thromboplastin was especially suitable. With this reagent, the results were also reproducible at high sample dilutions (1:80, factor II and X; 1:160, factor V). Because of the low sensitivity of non‐standardized human placenta thromboplastin to factor VII, measurements of this factor at a sample dilution of 1:40 required a standardized human placenta, or rabbit brain thromboplastin had to be used. For factor II measurements, the selection of a suitable deficient plasma is particularly important. Here, the reference curve showed a clear dependence on the commercial preparation chosen. Zusammenfassung Zur Optimierung der Faktor II‐, V‐, VII‐ und X‐Aktivitätsbestimmung beim Hund wurden Hundepoolplasma‐Verdünnungsreihen für verschiedene kommerzielle Calcium‐Thrombopla‐stine und Mangelplasmen erstellt. Gemessen an einer caninen Referenzkurve betrug die Einzelfaktoraktivität von humanem Referenzplasma 89% (Faktor II), 13% (Faktor V), 27% (Faktor VII) und 84% (Faktor X). Aufgrund der im Vergleich zum Menschen vielfachen höheren Faktor V‐ und VII‐Aktivität des Hundes ist bei der Messung mit humanem Mangelplasma eine hohe Probenvorverdünnung von mindestens 1:40 sinnvoll. Andernfalls könnten extreme Faktor V‐ und VII‐Aktivitätsschwankungen auch die Meßwerte anderer Einzelfaktoren beeinflussen. Für die Messung der Faktor II‐, V‐ und X‐Aktivität zeigte sich deshalb ein nicht standardisiertes Humanplazenta‐Thromboplastin besonders geeignet, womit die Ergebnisse auch bei hoher Probenverdünnung (1:80: Faktor II und X; 1:160: Faktor V) gut reproduzierbar waren. Aufgrund der geringen Faktor VII‐Empfindlichkeit von nicht standardisiertem Humanplazenta‐Thromboplastin muß allerdings bei der Messung dieses Faktors bei einer Probenverdünnung von 1:40 auf standardisiertes Humanplazenta‐oder Kaninchenhirn‐Thromboplastin zurückgegriffen werden. Besonders bei der Faktor II‐Messung ist ebenfalls die Auswahl eines geeigneten Mangelplasmas zu beachten. Hier ergaben sich deutliche Unterschiede zwischen verschiedenen kommerziellen Präparationen.

show abstract

Methylprednisolon-induzierte Hemmung des sympathischen Vasomotorentonus im hämorrhagischen Schock

Horeyseck

Thämer

1978

95. Kongreß Der Deutschen Gesellschaft Für Chirurgie, München, 3. Bis 6. Mai 1978

View full text Add to dashboard Cite

Prophylaktische Therapie mit Methylprednisolon und Heparin bei experimentellem Trauma und hämorrhagischem Schock

Cited by 3 publications

References 2 publications

Review article: Early steroid administration for traumatic haemorrhagic shock: A systematic review

Review article: Early steroid administration for traumatic haemorrhagic shock: A systematic review

Methodische Aspekte für die koagulometrische Aktivitätsbestimmung der Gerinnungsfaktoren II, V, VII und X aus Hundeplasma

Methylprednisolon-induzierte Hemmung des sympathischen Vasomotorentonus im hämorrhagischen Schock

Contact Info

Product

Resources

About